Astragaloside IV Mitigates Hepatocyte Apoptosis in Metabolic Dysfunction–Associated Fatty Liver Disease Through Inhibition of CASP3 ‐Dependent PARP1 Cleavage
Phytotherapy Research · 13.11.2026
DOI: 10.1002/ptr.70473 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytotherapy Research, online erschienen am 13.11.2026. Verfasst von Fengyi Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Shandong University of Traditional Chinese Medicine, Jinan, China. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Shandong Province, Special funding for Mount Tai Scholar Project, Shandong University of Traditional Chinese Medicine Quality Improvement and Innovation Project.
Abstract (Originalsprache)
Metabolic dysfunction–associated fatty liver disease (MAFLD) is associated with hepatic lipid accumulation, inflammation, and hepatocyte apoptosis. Astragaloside IV (AS‐IV) has been reported to regulate lipid metabolism, but its effects on hepatocyte apoptosis in MAFLD remain unclear. We investigated the effects of AS‐IV in db/db mice and free fatty acid (FFA)–treated HepG2 cells using biochemical assays, histological staining, measurements of inflammatory markers and reactive oxygen species, and apoptosis assays. Network pharmacology and molecular docking were used to identify candidate targets, followed by analyses of CASP3 and PARP1 expression and cleavage and CASP3 overexpression experiments. AS‐IV reduced hepatic and cellular triglyceride accumulation, inflammatory markers, and hepatocyte apoptosis, and improved liver histology and serum markers of liver injury in db/db mice. These effects were accompanied by reduced CASP3 activation and PARP1 cleavage. In HepG2 cells, AS‐IV also attenuated the changes associated with CASP3 overexpression. Together, these findings suggest that suppression of CASP3‐associated PARP1 cleavage may contribute to the protective effects of AS‐IV in these experimental models of MAFLD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Shandong University of Traditional Chinese Medicine, Jinan, China.
- The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.
ORCID-Profile: Fengyi Zhang, Xinhe Wang, Wenbo Wang, Yujie Li
Förderung
- Natural Science Foundation of Shandong Province
- Special funding for Mount Tai Scholar Project
- Shandong University of Traditional Chinese Medicine Quality Improvement and Innovation Project
Zitieren
APA
Zhang, F., Wang, X., Li, Y., Ma, W., Chen, Y., Zhang, Y., Zhang, J., Wang, X., Pan, J., Zhang, Y., Cheng, Z., Wang, W., & Li, Y. (2026). Astragaloside IV Mitigates Hepatocyte Apoptosis in Metabolic Dysfunction–Associated Fatty Liver Disease Through Inhibition of CASP3 ‐Dependent PARP1 Cleavage. Phytotherapy Research. https://doi.org/10.1002/ptr.70473
Vancouver
Zhang F, Wang X, Li Y, Ma W, Chen Y, Zhang Y, et al. Astragaloside IV Mitigates Hepatocyte Apoptosis in Metabolic Dysfunction–Associated Fatty Liver Disease Through Inhibition of CASP3 ‐Dependent PARP1 Cleavage. Phytotherapy Research. 2026. doi:10.1002/ptr.70473
BibTeX
@article{Zhang2026,
author = {Zhang, Fengyi and Wang, Xinhe and Li, Yahui and Ma, Wenlu and Chen, Yaxin and Zhang, Yufeng and Zhang, Jiayi and Wang, Xin and Pan, Jingjing and Zhang, Yu and Cheng, Ziyang and Wang, Wenbo and Li, Yujie},
title = {Astragaloside IV Mitigates Hepatocyte Apoptosis in Metabolic Dysfunction–Associated Fatty Liver Disease Through Inhibition of CASP3 ‐Dependent PARP1 Cleavage},
journal = {Phytotherapy Research},
year = {2026},
doi = {10.1002/ptr.70473}
}
EUVIMED